Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05996471 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
A Phase 2 study of HIV Infections, sponsored by ViiV Healthcare.
- Active
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT05996471 is a Phase 2 study of HIV Infections that is active but no longer recruiting, run by ViiV Healthcare. The registered enrollment target is 185 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05996471, a Phase 2 study of HIV Infections, is active but no longer recruiting, sponsored by ViiV Healthcare.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV. VH3810109 plus rHuPH20 plus Cabotegravir arm of the study has been discontinued based on preliminary results. The study will be conducted in 3 parts followed by a Long-Term Follow-up phase (LTFU).
Conditions Studied
Interventions
- BIOLOGICAL VH3810109
- DRUG Cabotegravir
- DRUG Standard of care (SOC)
- BIOLOGICAL rHuPH20
Study Locations (20)
Florida
- GSK Investigational Site - Fort Lauderdale
- GSK Investigational Site - Ft. Pierce
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
- GSK Investigational Site - Pensacola
- GSK Investigational Site - Sarasota
- GSK Investigational Site - Vero Beach
- GSK Investigational Site - West Palm Beach
California
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Palm Springs
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Francisco
District of Columbia
- GSK Investigational Site - Washington D.C.
- GSK Investigational Site - Washington D.C.
Alabama
- GSK Investigational Site - Birmingham
Connecticut
- GSK Investigational Site - New Haven
Georgia
- GSK Investigational Site - Decatur
Illinois
- GSK Investigational Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2028-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05996471
The ClinicalTrials.gov registry entry for NCT05996471 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (59% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which VH3810109 is the first listed.
NCT05996471 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05996471 about?
NCT05996471 is a clinical study titled "A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)". The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosi...
What is the current status of trial NCT05996471?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2023-08-17. Estimated completion is 2028-11-09.
What conditions does trial NCT05996471 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT05996471?
The interventions under investigation include: VH3810109 (BIOLOGICAL), Cabotegravir (DRUG), Standard of care (SOC) (DRUG), rHuPH20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05996471?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05996471 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.